Ocular Therapeutix Inc. (OCUL) Appears Highly Attractive Following SOL-1 Clinical Trial Data [Yahoo! Finance]
Ocular Therapeutix, Inc. (OCUL)
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ocutx.com
Company Research
Source: Yahoo! Finance
On April 13, William Blair maintained an Outperform rating on Ocular Therapeutix (NASDAQ:OCUL) right after the presentation of additional SOL-1 clinical trial data. According to the firm, this post-hoc investigation unequivocally supports Axpaxli's overall effectiveness and durability. In particular, starting at week 8, the treatment showed prolonged disease control over aflibercept, resulting in improvements in the median time to more than or equal to 30-micrometer and 75-micrometer increases in central subfield thickness at 23 and 22 weeks. M. A. Arkhipov/Shutterstock.com Additionally, patients with poorer initial baseline measurements showed higher treatment improvements, according to quartile analyses contextualizing visual acuity increases. The underlying safety characteristics are essentially unchanged. In addition to publishing detailed patient-level information about past intraocular inflammation instances, the company has said that drug particles that were first classifi
Show less
Read more
Impact Snapshot
Event Time:
OCUL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUL alerts
High impacting Ocular Therapeutix, Inc. news events
Weekly update
A roundup of the hottest topics
OCUL
News
- How The SOL-1 Readout Is Reframing The Story For Ocular Therapeutix (OCUL) [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMDGlobeNewswire
- Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026GlobeNewswire
- Ocular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 Data [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix™ to Participate in May Scientific and Investor ConferencesGlobeNewswire
OCUL
Earnings
- 11/4/25 - Beat
OCUL
Sec Filings
- 4/13/26 - Form 4
- 3/27/26 - Form SCHEDULE
- 2/27/26 - Form 8-K
- OCUL's page on the SEC website